Sigrid Therapeutics Advances Oral Health with Global Licensing of SiPore® Technology
Sigrid Therapeutics, a pioneering Swedish consumer health company focusing on metabolic health, has announced an exciting new partnership that aims to revolutionize the oral health sector. Following the success of its initial products, Carb Fence and Glucose Stabiliser, Sigrid is making headlines once again by entering into an exclusive global licensing and research agreement with a leading multinational consumer health corporation. This strategic collaboration will leverage Sigrid's innovative SiPore® technology, facilitating its transition into the realm of consumer oral health.
The SiPore® platform is renowned for its non-systemic material technology, consisting of custom-engineered porous silica particles designed to eliminate harmful proteins and enzymes responsible for plaque and biofilm buildup in the mouth. By utilizing a purely mechanical mode of action, SiPore® provides immediate and enduring protection against the development of plaque and dental caries without causing systemic exposure. With the increase of oral diseases affecting approximately 3.5 billion individuals globally, the launch of products utilizing SiPore® aims to directly address a critical health concern.
Sana Alajmovic, Co-Founder and CEO of Sigrid, underscored the importance of this collaboration, stating, "While our primary focus remains the continued commercialization of Carb Fence and Glucose Stabiliser, this partnership allows us to realize additional value from the SiPore® platform through a capital-efficient, non-dilutive approach." This partnership stands as a testament to the extensive two-year scientific, technical, and commercial validation that SiPore® underwent prior to its integration into consumer oral health products.
The terms of the agreement encompass the use of SiPore® across a variety of consumer oral health formulations. As part of the collaboration, Sigrid will benefit from upfront payments, developmental and clinical milestone payments, along with an array of royalties based on net sales—a financial model designed to maximize the potential value of this transformative technology.
The toothpaste market, valued at approximately USD 19 billion, is on course to reach USD 28 billion by 2034, driven by a growing emphasis on preventive health, premium formulations, and scientifically-backed daily-use products. Given this burgeoning market, the timing of Sigrid’s partnership is astute, merging innovative technology with genuine consumer needs in the oral health sector.
Damir Konakovic, the Head of Oral Health at Sigrid, emphasized the critical nature of safety, efficacy, and every day usability in oral health products. The collaboration with a seasoned industry partner is expected to facilitate rigorous scientific validation for the SiPore® technology while also enabling substantial reach to consumers worldwide. The integration of this cutting-edge solution into oral health formulations promises to transform daily oral care routines for millions, ensuring that safety and efficacy remain paramount.
As the industry moves forward, Sigrid Therapeutics demonstrates a strong commitment to advancing health innovations. By harnessing the potential of the SiPore® technology in this manner, the company not only reinforces its position in consumer health but also plays an instrumental role in addressing one of the most prevalent health issues worldwide. With ongoing developments and anticipated product launches on the horizon, Sigrid is poised to make a significant impact in promoting oral health for consumers aged 1 to 100. Visit www.sigridthx.com for more information on Sigrid Therapeutics and its innovative health solutions.
The SiPore® platform is renowned for its non-systemic material technology, consisting of custom-engineered porous silica particles designed to eliminate harmful proteins and enzymes responsible for plaque and biofilm buildup in the mouth. By utilizing a purely mechanical mode of action, SiPore® provides immediate and enduring protection against the development of plaque and dental caries without causing systemic exposure. With the increase of oral diseases affecting approximately 3.5 billion individuals globally, the launch of products utilizing SiPore® aims to directly address a critical health concern.
Sana Alajmovic, Co-Founder and CEO of Sigrid, underscored the importance of this collaboration, stating, "While our primary focus remains the continued commercialization of Carb Fence and Glucose Stabiliser, this partnership allows us to realize additional value from the SiPore® platform through a capital-efficient, non-dilutive approach." This partnership stands as a testament to the extensive two-year scientific, technical, and commercial validation that SiPore® underwent prior to its integration into consumer oral health products.
The terms of the agreement encompass the use of SiPore® across a variety of consumer oral health formulations. As part of the collaboration, Sigrid will benefit from upfront payments, developmental and clinical milestone payments, along with an array of royalties based on net sales—a financial model designed to maximize the potential value of this transformative technology.
The toothpaste market, valued at approximately USD 19 billion, is on course to reach USD 28 billion by 2034, driven by a growing emphasis on preventive health, premium formulations, and scientifically-backed daily-use products. Given this burgeoning market, the timing of Sigrid’s partnership is astute, merging innovative technology with genuine consumer needs in the oral health sector.
Damir Konakovic, the Head of Oral Health at Sigrid, emphasized the critical nature of safety, efficacy, and every day usability in oral health products. The collaboration with a seasoned industry partner is expected to facilitate rigorous scientific validation for the SiPore® technology while also enabling substantial reach to consumers worldwide. The integration of this cutting-edge solution into oral health formulations promises to transform daily oral care routines for millions, ensuring that safety and efficacy remain paramount.
As the industry moves forward, Sigrid Therapeutics demonstrates a strong commitment to advancing health innovations. By harnessing the potential of the SiPore® technology in this manner, the company not only reinforces its position in consumer health but also plays an instrumental role in addressing one of the most prevalent health issues worldwide. With ongoing developments and anticipated product launches on the horizon, Sigrid is poised to make a significant impact in promoting oral health for consumers aged 1 to 100. Visit www.sigridthx.com for more information on Sigrid Therapeutics and its innovative health solutions.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.